Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Acute Lung Injury Market Forecast: What Market Value Is Expected By 2030?
The market for acute lung injury experienced a consistent expansion lately, projecting a rise from $2.59 billion in 2025 to $2.71 billion in 2026, reflecting a compound annual growth rate of 4.4%. Factors contributing to this past growth trajectory included the elevated incidence of pneumonia and lung injuries stemming from trauma, restricted availability of sophisticated ventilation equipment, increasing consciousness surrounding critical care, the implementation of standardized fluid management practices, and the prevailing reliance on hospital-centric treatments.
The global market for acute lung injury is poised for consistent expansion over the coming years, projecting a valuation of $3.19 billion by 2030 with a compound annual growth rate of 4.2%. This anticipated growth stems from advancements in new drug therapies for ALI, the increasing incorporation of artificial intelligence into patient care, the worldwide expansion of intensive care units, a greater uptake of tailored treatment approaches, and improvements in less invasive ventilation methods. Key developments shaping this market period include a global rise in ALI occurrences, enhanced utilization of mechanical ventilation techniques, more widespread application of drug therapies and fluid management strategies, a heightened emphasis on early detection and tracking tools, and the broadening of critical care services within hospital settings.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20704&type=smp
Acute Lung Injury Market Growth Factors Supporting Long-Term Expansion
The expanding incidence of ailments affecting the respiratory system is anticipated to be a key catalyst for the development of the acute lung injury market. These respiratory conditions, which impact the lungs and the broader respiratory tract, result in breathing difficulties and compromised lung capacity. Factors contributing to the increased occurrence of these diseases include escalating air pollution, tobacco use, inactive lifestyles, an aging demographic, and the effects of viral outbreaks. Conditions such as pneumonia can precipitate acute lung injury by inducing significant inflammation and damaging the delicate air sacs (alveoli) in the lungs, thereby hindering the vital process of gas exchange and leading to respiratory distress. For illustration, the National Asthma Council, a non-profit entity based in Australia, reported that in 2023, Australia registered 474 fatalities linked to asthma, with 325 being female and 149 male, a number remarkably close to the 473 asthma-related deaths documented in 2022, indicating a steady pattern in asthma mortality across these two years. Consequently, the growing prevalence of respiratory diseases is a significant driver for the expansion of the acute lung injury market.
#Acute Lung Injury Market Segment Landscape And Growth Potential
The acute lung injury market covered in this report is segmented –
1) By Injury Type: Direct Injury, Indirect Injury
2) By Therapy: Mechanical Ventilation, Pharmacotherapy, Fluid Management, Other Therapies
3) By End User: Hospitals, Clinics, Other End Users
Subsegments:
1) By Direct Injury: Trauma-Induced Acute Lung Injury, Aspiration Pneumonitis, Pneumonia-Related Acute Lung Injury, Inhalation Injury
2) By Indirect Injury: Sepsis-Related Acute Lung Injury, Shock-Induced Acute Lung Injury, Acute Lung Injury Due To Blood Transfusion, Acute Lung Injury Associated With Pancreatitis
Acute Lung Injury Market Industry Trends Shaping Future Revenue Growth
Leading corporations within the acute lung injury treatment sector are dedicating their efforts toward creating cutting-edge therapies, exemplified by recombinant human plasma gelsolin (rhu-pGSN), with the aim of restoring equilibrium to errant inflammatory processes, modulating crucial immunological reactions, and ultimately enhancing the prognosis for individuals suffering from severe lung compromise. The foundation of recombinant human plasma gelsolin (rhu-pGSN) lies in gelsolin, a universally preserved protein instrumental in managing immune system imbalances observed in acute respiratory distress syndrome (ARDS). A notable development occurred in June 2025 when BioAegis Therapeutics, a biotechnology firm headquartered in the United States, secured Fast Track designation from the U.S. Food and Drug Administration (FDA) for its primary investigational product, rhu-pGSN, intended for the therapeutic management of ARDS. This innovative treatment presents a distinct set of advantages, encompassing the restoration of inflammatory balance without compromising overall immune capacity, the precise regulation of vital immune responses within the pulmonary system, and the potential for improved results among patients experiencing severe inflammatory lung damage.
Acute Lung Injury Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the acute lung injury market are Medtronic plc, Baxter International Inc., GE Healthcare Technologies Inc., Drägerwerk AG & Co. KGaA, Getinge AB, Koninklijke Philips N.V., Hamilton Medical AG, Vyaire Medical Inc., Vapotherm Inc., GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Faron Pharmaceuticals Oy, Windtree Therapeutics Inc., Apeiron Biologics AG, ReAlta Life Sciences Inc., Vasomune Therapeutics Inc., MediciNova Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc.
Access The Complete Acute Lung Injury Market Report:
https://www.thebusinessresearchcompany.com/report/acute-lung-injury-global-market-report
Acute Lung Injury Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the acute lung injury market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the acute lung injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
